Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

In South Kivu, MSF ran a mass immunization campaign in Fizi health zone that aims to vaccinate 120,000 children between the ages of 6 months and 15 years against measles over a period of six weeks. Photograph by Haavar Karlsen
Press release
Press release |
11 October 2022
Vaccines

MSF responds to WHO approval of South Africa’s vaccine regulatory system

3 min
GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017. Photo credit: Borja Ruiz Rodriguez/MSF
Press release
Press release |
14 September 2022
Diagnostics Tuberculosis

MSF warns that supply delays of critical TB test will cost lives

4 min
Juba, South Sudan. Cholera vaccination at the Protection of Civilians (PoC) site in Tomping. Photograph by MSF
Press release
Press release |
31 August 2022
Vaccines
Africa

MSF responds to agreement between Aspen Pharmacare and Serum Institute of India to produce four routine vaccines in South Africa

2 min
Herman gets tested for HIV in the PODI Ouest in Kinshasa, Democratic Republic of Congo. The PODIs, which are run by the RNOAC group of people with HIV, offer testing, support and Antiretroviral drugs (ARVs) to stable HIV patients in the capital. Photograph by Tommy Trenchard
Press release
Press release |
28 July 2022
HIV/AIDS

Following WHO recommendation, access to new game-changing HIV prevention drug needs to be accelerated

4 min
Jérôme Tognotti, MSF nurse supervisor, holding a vial of COVID vaccine used by teams to vaccinate homeless and migrant people Photograph by Nicolas Guyonnet
Press release
Press release |
24 June 2022
COVID-19

MSF responds to BioNTech announcement that it will set up first “BioNTainers” by end of 2022

3 min
"" Photograph by Severine Blanchet
Press release
Press release |
23 June 2022
Tropical & neglected diseases
Rwanda

MSF warns that reduced funding for Neglected Tropical Diseases could be devastating

3 min
Trips WAIVER protest at MC12 event in Geneva, Switzerland
Press release
Press release |
17 June 2022
COVID-19

Inability to agree a real pandemic intellectual property Waiver at WTO is a devastating global failure for people the world over

3 min
"" Photograph by MSF
Press release
Press release |
15 June 2022
COVID-19

Trade Ministers at WTO should not accept current draft of Ministerial Decision on TRIPS

5 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury